Reports of treatment of SR-aGVHD, 2012 to 2019
| Agent . | Retrospective . | Prospective . | Total . |
|---|---|---|---|
| Alemtuzumab | 1 | 1 | 2 |
| α-1 Antitrypsin | 0 | 2 | 2 |
| ATG | 2 | 1 | 3 |
| CD25 antibody | 2 | 4 | 6 |
| CD 25 antibody + mycophenolate mofetil | 1 | 0 | 1 |
| CD25 antibody or etanercept | 1 | 0 | 1 |
| CD 25 antibody + infliximab | 1 | 0 | 1 |
| CD25 antibody + etanercept | 0 | 1 | 1 |
| Brentuximab vedotin | 0 | 1 | 1 |
| CD3/CD7 immunotoxin | 0 | 1 | 1 |
| Decidua stromal cells | 2 | 1 | 3 |
| Etanercept | 4 | 1 | 5 |
| ECP | 10 | 2 | 12 |
| Infliximab | 3 | 0 | 3 |
| Intra-arterial steroids | 2 | 2 | 4 |
| Mesenchymal stromal cells | 8 | 13 | 21 |
| Methotrexate | 1 | 0 | 1 |
| Mycophenolate mofetil | 3 | 0 | 3 |
| Pentostatin | 2 | 0 | 2 |
| Ruxolitinib | 4 | 1 | 5 |
| Tacrolimus + sirolimus or everolimus | 0 | 1 | 1 |
| Tocilizumab | 1 | 0 | 1 |
| Vedolizumab | 1 | 0 | 1 |
| Total | 49 | 32 | 81 |
| Agent . | Retrospective . | Prospective . | Total . |
|---|---|---|---|
| Alemtuzumab | 1 | 1 | 2 |
| α-1 Antitrypsin | 0 | 2 | 2 |
| ATG | 2 | 1 | 3 |
| CD25 antibody | 2 | 4 | 6 |
| CD 25 antibody + mycophenolate mofetil | 1 | 0 | 1 |
| CD25 antibody or etanercept | 1 | 0 | 1 |
| CD 25 antibody + infliximab | 1 | 0 | 1 |
| CD25 antibody + etanercept | 0 | 1 | 1 |
| Brentuximab vedotin | 0 | 1 | 1 |
| CD3/CD7 immunotoxin | 0 | 1 | 1 |
| Decidua stromal cells | 2 | 1 | 3 |
| Etanercept | 4 | 1 | 5 |
| ECP | 10 | 2 | 12 |
| Infliximab | 3 | 0 | 3 |
| Intra-arterial steroids | 2 | 2 | 4 |
| Mesenchymal stromal cells | 8 | 13 | 21 |
| Methotrexate | 1 | 0 | 1 |
| Mycophenolate mofetil | 3 | 0 | 3 |
| Pentostatin | 2 | 0 | 2 |
| Ruxolitinib | 4 | 1 | 5 |
| Tacrolimus + sirolimus or everolimus | 0 | 1 | 1 |
| Tocilizumab | 1 | 0 | 1 |
| Vedolizumab | 1 | 0 | 1 |
| Total | 49 | 32 | 81 |
See supplemental Table 1 for details.